What is Roth Capital’s Estimate for SPRY Q3 Earnings?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Analysts at Roth Capital issued their Q3 2025 earnings estimates for shares of ARS Pharmaceuticals in a report released on Thursday, September 4th. Roth Capital analyst J. Wittes forecasts that the company will post earnings per share of ($0.44) for the quarter. Roth Capital currently has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. Roth Capital also issued estimates for ARS Pharmaceuticals’ Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.63) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at $0.77 EPS, FY2028 earnings at $2.06 EPS and FY2029 earnings at $4.06 EPS.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.05). The company had revenue of $15.72 million during the quarter, compared to analyst estimates of $12.92 million. ARS Pharmaceuticals had a negative net margin of 42.74% and a negative return on equity of 21.85%.

Separately, Wall Street Zen downgraded shares of ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $32.50.

ARS Pharmaceuticals Stock Down 5.8%

Shares of SPRY opened at $10.07 on Monday. The firm has a market cap of $995.22 million, a PE ratio of -20.55 and a beta of 0.88. The company’s fifty day moving average is $15.90 and its two-hundred day moving average is $14.38. ARS Pharmaceuticals has a fifty-two week low of $9.97 and a fifty-two week high of $18.90. The company has a quick ratio of 5.98, a current ratio of 6.17 and a debt-to-equity ratio of 0.37.

Insider Activity

In related news, CFO Kathleen D. Scott sold 12,500 shares of ARS Pharmaceuticals stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $187,500.00. Following the sale, the chief financial officer owned 10,042 shares of the company’s stock, valued at $150,630. The trade was a 55.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder James E. Flynn sold 740,149 shares of the firm’s stock in a transaction on Friday, June 27th. The stock was sold at an average price of $18.46, for a total transaction of $13,663,150.54. Following the transaction, the insider directly owned 4,887,254 shares of the company’s stock, valued at approximately $90,218,708.84. This represents a 13.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 882,649 shares of company stock worth $15,773,760 over the last three months. 33.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Bernard Wealth Management Corp. acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at about $27,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of ARS Pharmaceuticals in the 1st quarter valued at about $37,000. PNC Financial Services Group Inc. boosted its holdings in shares of ARS Pharmaceuticals by 78,100.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company’s stock valued at $49,000 after buying an additional 3,905 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at about $75,000. Finally, Osaic Holdings Inc. boosted its holdings in shares of ARS Pharmaceuticals by 52.8% in the 2nd quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock valued at $91,000 after buying an additional 1,803 shares during the period. 68.16% of the stock is owned by institutional investors and hedge funds.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.